Home
|
Contact Us
|
1.866.566.5636
History
Leadership
Strategic Alliances
Intellectual Property
Code of Ethics
Contact Us
Bioadhesive Delivery
Women's Health
CRINONE® 8% (progesterone gel)
CRINONE 4% (progesterone gel)
OTC Products
Men's Health
STRIANT® (testosterone buccal system)
Overview
Preterm Birth/Short Cervix
Overview
Management Team
Board of Directors
Board Committees
Audit Committee
Compensation Committee
Nominating Committee
Press Releases
2012
2011
2010
2009
2008
2007
Events
Annual Report
SEC Filings
XBRL Filings
Code of Ethics
Stock Ownership
FAQs
Contact Us
Overview
Management Team
Board of Directors
Board Committees
Press Releases
2012
2011
2010
2009
2008
2007
Events
Annual Report
SEC Filings
Code of Ethics
Stock Ownership
FAQs
Contact Us
Press Releases - 2012
5/4/2012
Columbia Laboratories Reports First Quarter 2012 Financial Results
LIVINGSTON, NJ - May 4, 2012- Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results for the three-month period ended March 31, 2012. Highlights of the first quarter include:
4/24/2012
Columbia Laboratories to Discuss First Quarter 2012 Financial Results on May 4 Conference Call
LIVINGSTON, NJ — April 24, 2012 — Columbia Laboratories Inc. (Nasdaq: CBRX) will hold a conference call on May 4, 2012, to discuss financial results of the three-month period ended March 31, 2012. Frank Condella, president and chief executive officer, and Lawrence Gyenes, senior vice president, chief financial officer and treasurer of Columbia Laboratories, will host the call.
3/13/2012
Columbia Laboratories Hires Cowen and Company to Assist in Evaluating Potential Strategic Transactions
LIVINGSTON, NJ — March 13, 2012 —Columbia Laboratories Inc. (Nasdaq: CBRX) has engaged Cowen and Company, LLC (“Cowen”) as its independent financial advisor to assist the Company with its stated goal to evaluate possible strategic transactions.
3/8/2012
Columbia Laboratories Reports Fourth Quarter and Year-End 2011 Financial Results
LIVINGSTON, NJ - March 8, 2012 - Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results for the three- and twelve-month periods ended December 31, 2011.
3/6/2012
Columbia Laboratories Receives Nasdaq Minimum Bid Price Non-compliance Letter
LIVINGSTON, NJ — March 6, 2012 — Columbia Laboratories Inc. (Nasdaq: CBRX) received a notice on March 6, 2012, from the Nasdaq Stock Market indicating that it no longer meets the minimum bid price requirement for continued listing on the Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Rule”). The notice stated that the bid price of the Company's common stock has closed below the required minimum $1.00 per share for the previous 30 consecutive business days. The Nasdaq notice has no immediate effect on the listing of the Company's common stock.
3/1/2012
Columbia Laboratories to Discuss Fourth Quarter and Year-end 2011 Financial Results on March 8, 2012, Conference Call
LIVINGSTON, NJ — March 1, 2012 — Columbia Laboratories Inc. (Nasdaq: CBRX) will hold a conference call on March 8, 2012, to discuss financial results of the three- and twelve-month periods ended December 31, 2011. Frank Condella, president and chief executive officer, and Lawrence Gyenes, senior vice president, chief financial officer and treasurer of Columbia Laboratories, will host the call.
3/1/2012
Columbia Laboratories Announces 42% Workforce Reduction
LIVINGSTON, NJ — March 1, 2012 — Columbia Laboratories Inc. (Nasdaq: CBRX) today announced a 42% workforce reduction from 24 employees at December 31, 2011, to 14 employees. The Company will record a severance charge of approximately $0.5 million in the first quarter of 2012, and expects to realize annual savings of over $1.5 million.
2/29/2012
Columbia Laboratories will present March 5th at Cowen and Company Health Care Conference
LIVINGSTON, NJ — February 29, 2012 — Columbia Laboratories Inc. (Nasdaq: CBRX) announced today that Frank Condella, president and chief executive officer, will present at the Cowen and Company 32nd Annual Health Care Conference.
2/27/2012
Watson Receives Complete Response Letter from FDA for Progesterone Vaginal Gel 8%
PARSIPPANY and LIVINGSTON, NJ— February 27, 2012 — Watson Pharmaceuticals, Inc. (NYSE: WPI) and Columbia Laboratories, Inc. (Nasdaq: CBRX) today confirmed that, as expected, Watson has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA 22-139) for progesterone vaginal gel 8% for use in the reduction of risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy.
2/13/2012
Columbia Laboratories Transfers NDA for Progesterone Vaginal Gel 8% to Watson Pharmaceuticals
LIVINGSTON and PARSIPPANY, NJ— February 13, 2012 — Columbia Laboratories, Inc. (Nasdaq: CBRX), and Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that Columbia has transferred the new drug application for progesterone vaginal gel 8% for use in the reduction of risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy (NDA 22-139) to Watson.
1/20/2012
FDA Advisory Committee Declines to Recommend Approval of Progesterone Vaginal Gel 8% for the Reduction of Risk of Preterm Birth in Women with Short Uterine Cervical Length
LIVINGSTON and PARSIPPANY, NJ— January 20, 2012 — Columbia Laboratories, Inc. (Nasdaq: CBRX), and Watson Pharmaceuticals, Inc. (NYSE: WPI), today confirmed that the Advisory Committee for Reproductive Health Drugs of the U.S. Food and Drug Administration (FDA) did not recommend approval of progesterone vaginal gel 8% for the reduction of risk of preterm birth in women with short uterine cervical length at the mid-trimester of pregnancy. While panel members generally agreed that progesterone vaginal gel 8% is safe, the panel stated that more information is needed to support approval.
